Skip to content
DataLookout
Menu

SADIE2NCT05972564

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 30, 2026 to Jun 30, 2027
    • Eligibility criteria expanded, about 5 words
    • Study completion pushed from Dec 30, 2026 to Dec 30, 2027
  2. Notable Eligibility criteria expanded, about 23 wordsv7
  3. Notable Eligibility criteria shortened, about 2 wordsv5
  4. Notable Eligibility criteria revisedv4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 30, 2023 to Sep 6, 2023
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adipose tissue macrophages
Timeframe: 12 weeks
Flow mediated dilation
Timeframe: 12 weeks
Monocyte chemoattractant protein-1
Timeframe: 12 weeks

Secondary (2)

Pro-inflammatory T cells
IL-6

Arms and interventions

Empagliflozin ArmActive comparator

Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes. To ensure blinding, empagliflozin will be over-encapsulated in identical gelatin capsules as placebo.

Placebo ArmPlacebo comparator

Placebo consists of gelatin capsules.

Drugs: Empagliflozin 25 MG, Placebo

Sites

1 site in 1 country

  • Vanderbilt University Medical CenterNashville, Tennessee, United States